Ablexis

Ablexis is a small, privately held company based in San Diego, California, with three employees and annual revenue of $2.5 million. They specialize in developing and licensing groundbreaking technologies for the pharmaceutical industry. Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains meticulously designed to enhance the discovery and development of human therapeutic antibodies. These specialized mouse strains are highly versatile, capable of generating antibodies for a wide range of applications, including traditional IgGs, single-domain VH antibodies, multispecifics, antibody-drug conjugates (ADCs), chimeric antigen receptors (CARs), and T-cell receptors (TCRm), among others. The AlivaMab Mouse strains are renowned for producing high-quality antibodies with exceptional properties. Their unique design allows for broad combinatorial and somatic diversities, resulting in antibodies with high affinities, specificity, and excellent developability. These qualities make the antibodies generated using AlivaMab Mouse particularly well-suited for clinical development and therapeutic applications. To explore the potential of the AlivaMab Mouse platform or inquire about licensing opportunities, interested parties are encouraged to visit Ablexis' website at www.ablexis.com or contact the company directly at [email protected].